Coya Therapeutics enters $30M at-the-market equity offering with Leerink Partners

Coya Therapeutics, Inc.

• Sales Agreement with Leerink Partners allows up to $30M gross proceeds from common stock sales on Nasdaq.
• Leerink receives 3.0% commission on gross proceeds; Company may sell at its discretion.
• Offering under existing shelf registration; no minimum obligation to sell.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.